- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07530185
Effects of L-Tyrosine and Caffeine on Performance in Elite Boxers (TYCAF-BOX)
Effects of L-Tyrosine and Caffeine Supplementation on Cognitive, Physical, and Physiological Parameters in Elite Boxers: A Randomized Double-Blind Placebo-Controlled Crossover Study
Study Overview
Status
Conditions
Detailed Description
Participants will attend five sessions in total. The first session will be used for familiarization and baseline measurements, including resting physiological and cognitive assessments. The remaining four sessions will consist of randomized experimental conditions (placebo, L-tyrosine, caffeine, and combined supplementation), applied in a counterbalanced crossover design.
Each experimental session will be separated by a washout period of at least 72 hours. Supplements will be administered 60 minutes before exercise. Cognitive performance will be assessed using the Stroop test, and physical performance will be evaluated using a boxing-specific simulation protocol. Physiological responses, including heart rate and biochemical markers such as BDNF and oxidative stress parameters, will be measured.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Halil UÇAR
- Phone Number: +90 5462921133
- Email: halil.ucar@inonu.edu.tr
Study Locations
-
-
-
Erzurum, Turkey (Türkiye)
- Ataturk University Faculty of Sport Sciences
-
Contact:
- Halil UÇAR
- Phone Number: +90 5462921133
- Email: halil.ucar@inonu.edu.tr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Male elite boxers aged ≥18 years At least 8 years of boxing training experience Active participation in national or international competitions Regular training schedule No injury or illness affecting performance
Exclusion Criteria:
Use of nutritional supplements or stimulants within the last 4 weeks Any cardiovascular, metabolic, or neurological disorder Current injury or musculoskeletal limitation Smoking or excessive caffeine intake Failure to comply with study procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Participants receive placebo condition.
|
Placebo solution matched in taste and volume to active supplements.
|
|
Experimental: L-tyrosine
Participants receive L-tyrosine condition.
|
L-tyrosine at 150 mg/kg body weight administered 60 minutes before exercise.
|
|
Experimental: Caffeine
Participants receive caffeine condition.
|
Caffeine at 5 mg/kg body weight administered 60 minutes before exercise.
|
|
Experimental: Combined
Participants receive combined supplementation condition.
|
Combined L-tyrosine (150 mg/kg) and caffeine (5 mg/kg) administered 60 minutes before exercise.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Stroop Test Performance
Time Frame: up to 12 weeks
|
Cognitive performance assessed using the Stroop test, including reaction time and accuracy.
|
up to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
BDNF Levels
Time Frame: up to 12 weeks
|
Serum brain-derived neurotrophic factor levels measured before and after exercise.
|
up to 12 weeks
|
|
Oxidative Stress Markers
Time Frame: up to 12 weeks
|
Serum levels of total antioxidant status (TAS), total oxidant status (TOS), malondialdehyde (MDA), superoxide dismutase (SOD) activity, and glutathione peroxidase (GPx) activity will be measured.
|
up to 12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UcarPhD2026
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sports Performance
-
Universidade Federal de Santa CatarinaCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.CompletedEndurance Performance | Sports Nutritional Sciences | Sports PerformanceBrazil
-
Istinye UniversityActive, not recruitingAthletic Performance | Sports Physical Therapy | Football Players | Sports PerformanceTurkey
-
Bezmialem Vakif UniversityCompleted
-
University of Central LancashireCompletedSports PerformanceUnited Kingdom
-
İSMAİL CEYLANCompleted
-
New Damietta University HospitalCompletedSports PerformanceEgypt
-
Istanbul Bilgi UniversityCompletedSports Nutritional Sciences | Ergogenic Support | Sports Performance in Children | Ergogenic Athletic Performance | Sport NutritionTurkey (Türkiye)
-
Akdeniz UniversityNot yet recruiting
-
Texas Tech University Health Sciences CenterActive, not recruiting
-
Hacettepe UniversityCompletedSports Performance in ChildrenTurkey
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
AkesoNot yet recruitingAtopic DermatitisChina
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
Beijing Inno Medicine Co., Ltd.The TIMI Study GroupNot yet recruitingCoronary Artery Disease | AtherosclerosisChina